One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 26 points (0.2%) at 17,168 as of Friday, Oct. 16, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,423 issues advancing vs. 1,539 declining with 158 unchanged.

The Health Care sector currently sits down 0.4% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Valeant Pharmaceuticals International ( VRX), up 4.1%, Novo Nordisk A/S ( NVO), up 3.2%, Edwards Lifesciences ( EW), up 2.0%, Express Scripts ( ESRX), up 1.6% and Eli Lilly and ( LLY), up 1.3%. On the negative front, top decliners within the sector include Cempra ( CEMP), down 30.6%, Vertex Pharmaceuticals ( VRTX), down 1.9%, Regeneron Pharmaceuticals ( REGN), down 1.6% and Amgen ( AMGN), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Becton Dickinson ( BDX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Becton Dickinson is up $1.79 (1.3%) to $138.86 on light volume. Thus far, 363,258 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $137.19-$139.29 after having opened the day at $137.19 as compared to the previous trading day's close of $137.07.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. Becton Dickinson has a market cap of $28.5 billion and is part of the health services industry. Shares are down 1.5% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Becton Dickinson a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full Becton Dickinson Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Shire ( SHPG) is up $2.38 (1.2%) to $208.43 on average volume. Thus far, 347,865 shares of Shire exchanged hands as compared to its average daily volume of 890,100 shares. The stock has ranged in price between $207.38-$210.76 after having opened the day at $208.62 as compared to the previous trading day's close of $206.05.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $40.1 billion and is part of the drugs industry. Shares are down 5.7% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Shire a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Shire Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.68 (1.1%) to $60.79 on average volume. Thus far, 2.0 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $60.11-$61.25 after having opened the day at $60.35 as compared to the previous trading day's close of $60.11.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $49.0 billion and is part of the drugs industry. Shares are up 4.5% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Teva Pharmaceutical Industries Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).